Add-on effects of statin in simeprevir, peginterferon plus ribavirin combination therapy for chronic hepatitis C.

Add-on effects of statin in simeprevir, peginterferon plus ribavirin combination therapy for chronic hepatitis C. - Statin add onto simeprevir, peginterferon plus ribavirin therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012878

Enrollment

Registered

2014-01-22

Start date

2014-02-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

fluvastatin, simeprevir, peginterferon and ribavirin simeprevir, peginterferon and ribavirin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C patients, genotytpe 1

Exclusion criteria

Exclusion criteria: 1. prior treatment containing telaprevir 2. pregnant or possibly pregnant 3. patients with fertile partner 4. patients allergic to ribavirin or other nucleoside analogues

Design outcomes

Primary

Measure	Time frame
Sustained virological response (viral clearance rate on 24 weeks after treatment)	—

Countries

Japan

Contacts

Public ContactGoki Suda

Hokkaido University Hospital Department of Gastroenterology and Hepatology

gsudgast@pop.med.hokudai.ac.jp011-716-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026